DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs

Aug 04, 2011, 16:05 ET from DURECT Corporation

CUPERTINO, Calif., Aug. 4, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2011. Total revenues increased to $7.8 million for the three months ended June 30, 2011 from $7.3 million for the three months ended June 30, 2010.  Net loss for the three months ended June 30, 2011 was $5.2 million, compared to a net loss of $6.3 million for the same period in 2010.    

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

At June 30, 2011, we had cash and investments of $37.5 million, compared to cash and investments of $41.9 million at March 31, 2011 and $49.6 million at December 31, 2010.  We have no debt obligations, other than normal liabilities associated with running our business.

"We are supporting Pfizer in resolving the remaining issues related to REMOXY® and appreciate the experienced team Pfizer has dedicated to these efforts," stated James E. Brown, D.V.M., President and CEO of DURECT.  "We are 11 patients away from completing enrollment in our pivotal Phase III trial for POSIDUR™ (BESST), and we expect to have top-line data in the fourth quarter of this year.  In July, as a culmination of a multi-year feasibility effort between Zogenix and us, we added a new antipsychotic development program to our pipeline."

Update of Programs:

REMOXY.  On June 23, 2011, Pfizer received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the REMOXY New Drug Application (NDA) which had been resubmitted in December 2010.  The FDA's Complete Response Letter raised concerns related to, among other matters, the Chemistry, Manufacturing, and Controls (CMC) section of the NDA for REMOXY.  Pfizer is working to evaluate the issues described in the Complete Response Letter, has efforts underway to resolve these issues and plans to have further discussions with the FDA about them.  Resolution of these issues and potential regulatory approval of REMOXY in the U.S. is unlikely to occur in less than one year, and could be delayed significantly longer than a year.




REMOXY, an investigational drug, is a unique long-acting oral formulation of oxycodone intended to treat moderate to severe pain. Based on DURECT's ORADUR® technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to resist common methods of prescription drug misuse and abuse.  



POSIDUR (SABER™-Bupivacaine) Post-Operative Pain Relief Depot. During the second quarter of 2011, patient enrollment continued in our U.S. pivotal Phase III clinical study known as BESST (Bupivacaine Effectiveness and Safety in SABER Trial).  As of August 3, we had dosed 293 patients out of our target of 304.  At our current enrollment rate, we expect to complete enrollment in approximately a month.  We continue to anticipate reporting top-line data in the fourth quarter of 2011.  




POSIDUR is our post-operative pain relief depot that utilizes our patented SABER technology to deliver bupivacaine to provide up to three days of pain relief after surgery. POSIDUR is licensed to Hospira for commercialization in the U.S. and Canada, and to Nycomed for commercialization in Europe and other defined countries. We have retained commercialization rights in Japan and all other countries not subject to the Nycomed and Hospira licenses.



ELADUR (TRANSDUR®-Bupivacaine).  Pfizer completed its acquisition of King Pharmaceuticals (King) in February 2011 and as a result has assumed the development and commercialization rights and obligations to ELADUR.  In April 2011, we announced top-line results from a Phase II clinical trial conducted by King for the treatment of chronic low back pain.  The primary efficacy endpoint for the trial was not met.  We and Pfizer are continuing to analyze these data and will work together to determine next steps for ELADUR.




ELADUR is our proprietary transdermal patch intended to deliver bupivacaine for a period of up to three days from a single application.  ELADUR demonstrated a positive efficacy trend in a Phase 2a study for post-herpetic neuralgia (PHN); a poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on DURECT's website at www.durect.com/wt/durect/page_name/Publications.



TRANSDUR-Sufentanil.  In recent months, we have had discussions with the FDA and regulatory agencies in several major European countries to better understand development requirements for U.S. and European approval in furtherance of our development plans for TRANSDUR-Sufentanil.  We continue discussions with potential partners regarding licensing development and commercialization rights to this program to which we hold worldwide rights.




TRANSDUR-Sufentanil is our proprietary transdermal patch intended to deliver sufentanil to chronic pain sufferers for a period of up to seven days from a single application.



ORADUR-ADHD Program.  In the second quarter of 2011, we and Orient Pharma completed a Phase I pharmacokinetic study with multiple formulations.  We are continuing to optimize the formulation and are planning next steps in our ORADUR-ADHD program.



Relday™ (Risperidone Program).  In July 2011, we signed a development and license agreement with Zogenix to develop Relday, a product candidate targeting the antipsychotic market.  Zogenix will be responsible for the clinical development and commercialization of a proprietary, long-acting (once-monthly) injectable formulation of risperidone using DURECT's SABER controlled-release formulation technology in combination with Zogenix's DosePro® needle-free, subcutaneous drug delivery system.  DURECT will be responsible for non-clinical, formulation and CMC development activities and will be reimbursed by Zogenix for its research and development efforts on the product.  The existing long-acting injectable risperidone product, which achieved $1.5 billion in global net sales in 2010, requires twice-monthly, 2 mL intramuscular injections with a 21 gauge or larger needle.  Zogenix expects to initiate clinical studies for Relday in patients with schizophrenia in early 2012.  Under the terms of the agreement, Zogenix made an upfront payment of $2.25 million to DURECT in July, with the potential to pay DURECT up to an additional $103 million in future clinical, regulatory and commercial milestone payments based upon successful achievement of certain events.  Zogenix will have exclusive global rights to commercialize Relday and will pay DURECT a mid single-digit to low double-digit percentage royalty on net sales.



Feasibility Projects and Other Activities.  During the second quarter of 2011, we continued work on several feasibility projects as a means of demonstrating that our technologies can achieve the drug delivery objectives set forth by our collaborators and are worthy of further development.  The Zogenix program, described above, was one such project which has matured into a development and license agreement.



Earnings Conference Call

A live audio webcast of a conference call to discuss second quarter 2011 results will be broadcast live over the internet at 4:30 p.m. Eastern Time on August 4 and is available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR®, and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding Pfizer's on-going review and interactions with FDA regarding approval of the REMOXY NDA and the potential of resolving all outstanding regulatory concerns regarding REMOXY, anticipated completion of enrollment of BESST and receipt of top-line data for POSIDUR, future development activities and possible licensing transactions relating to TRANSDUR-Sufentanil, future development activities regarding ELADUR, anticipated optimization of a formulation for ORADUR-ADHD and next steps in that program, anticipated initiation of clinical studies for Relday in early 2012 and potential milestone payments and royalties receivable from Zogenix, and the potential benefits and uses of our drug candidates are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended endpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on May 4, 2011 under the heading "Risk Factors."

DURECT CORPORATION

STATEMENTS OF OPERATIONS DATA

(in thousands, except per share amounts)

(Unaudited)
























Three months ended


Six months ended




June 30,


June 30,




2011


2010


2011


2010











Collaborative research and development and other revenue

$  5,188


$  4,657


$  10,700


$    8,473

Product revenue, net

2,645


2,656


5,737


6,506


Total revenues

7,833


7,313


16,437


14,979











Operating expenses:









Cost of revenues (1)

1,085


861


2,486


2,239


Research and development (1)

8,708


9,204


18,588


18,625


Selling, general and administrative (1)

3,327


3,584


7,043


7,086


Total operating expenses

13,120


13,649


28,117


27,950











Loss from operations

(5,287)


(6,336)


(11,680)


(12,971)











Other income (expense):









Interest and other income

43


48


83


59


Interest and other expense

(1)


(21)


(5)


(23)

Net other income


42


27


78


36











Net loss


$ (5,245)


$ (6,309)


$ (11,602)


$ (12,935)











Net loss per share, basic and diluted

$   (0.06)


$   (0.07)


$     (0.13)


$     (0.15)











Shares used in computing basic and diluted net loss per share

87,404


86,845


87,338


86,801









































(1) Includes stock-based compensation related to the following:


















Cost of revenues


$       82


$       86


$       167


$       170

Research and development

1,072


1,290


2,199


2,567

Selling, general and administrative

580


663


1,151


1,332


Total stock-based compensation

$  1,734


$  2,039


$    3,517


$    4,069



DURECT CORPORATION

CONDENSED BALANCE SHEETS

(in thousands)











June 30, 2011


December 31, 2010 (1)





(unaudited)





ASSETS







Current assets:







   Cash and cash equivalents


$          5,486


$                    10,437



   Short-term investments


29,247


35,005



   Short-term restricted investments


-


66



   Accounts receivable


3,290


3,716



   Inventories


3,265


2,836



   Prepaid expenses and other current assets


1,251


2,785



Total current assets


42,539


54,845










Property and equipment, net


2,204


1,776



Goodwill


6,399


6,399



Intangible assets, net


62


71



Long-term investments


1,924


3,197



Long-term restricted Investments


867


867



Other long-term assets


349


405



Total assets


$        54,344


$                    67,560










LIABILITIES AND STOCKHOLDERS' EQUITY







Current liabilities:







   Accounts payable


$          1,001


$                         981



   Accrued liabilities


4,303


6,524



   Contract research liability


2,157


2,109



   Deferred revenue, current portion


8,079


8,079



   Other short-term liabilities


229


216



Total current liabilities


15,769


17,909










Deferred revenue, noncurrent portion


30,809


34,849



Other long-term liabilities


357


315










Stockholders’ equity


7,409


14,487



Total liabilities and stockholders’ equity


$        54,344


$                    67,560











 (1)  Derived from audited financial statements.  



SOURCE DURECT Corporation



RELATED LINKS

http://www.durect.com